Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies.
S
S
Sinha
M A
MA
Gertz
M Q
MQ
Lacy
A
A
Dispenzieri
S R
SR
Hayman
F K
FK
Buadi
D
D
Dingli
I N
IN
Micallef
W J
WJ
Hogan
D A
DA
Gastineau
S V
SV
Rajkumar
S K
SK
Kumar
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D013792:Thalidomide; D003520:Cyclophosphamide; D000077269:Lenalidomide